Medical tech startup MY01 collects $12.5m in Series A financing

• Investissement Québec led the round, with participation from Desjardins Capital and Fondaction
• MY01’s continuous compartmental pressure monitor aids in the diagnosis of compartment syndrome, a medical condition where pressure increases inside a muscle, which restricts blood flow and causes pain
• The round’s proceeds will be used to expand MY01’s commercialization activities in the US

MY01, a Montreal-based medical technology startup that uses microsensors to aid physicians in diagnosing compartment syndrome, has raised $12.5 million in Series A financing.

Investissement Québec led the round, with participation from Desjardins Capital and Fondaction.

MY01’s continuous compartmental pressure monitor (CCPM) aids in the diagnosis of compartment syndrome, a medical condition where pressure increases inside a muscle, which restricts blood flow and causes pain. If the pressure increases significantly and is not addressed, compartment syndrome can lead to amputation. The MY01 CCPM embeds a microsensor into the compartment and translates continuous pressure data to both a monitor and a mobile app.

The round’s proceeds will be used to expand MY01’s commercialization activities in the United States.

“This investment will support MY01’s goal of becoming the gold standard in the diagnosis of compartment syndrome,” said Charles Allan, CEO of MY01, in a statement. “Our growth has been significant since our launch in the United States and this funding will allow us to accelerate our development while improving patient outcomes.”